Learn when hypertrophic cardiomyopathy becomes severe and how a cardiologist guides you through heart transplant evaluation ...
MedPage Today on MSN
Mavacamten poised to expand to pediatric obstructive hypertrophic cardiomyopathy
The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...
1don MSN
Global trial shows targeted heart drug reduces obstructive hypertrophic cardiomyopathy in youth
A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication ...
Researchers at Children's Hospital of Philadelphia (CHOP) reported today that adolescents with hypertrophic cardiomyopathy (HCM) who took mavacamten experienced reduced obstruction, allowing blood to ...
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...
New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology ...
Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...
7h
Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
Bristol Myers Squibb recently reported that its Phase 3 SCOUT-HCM trial of Camzyos in adolescents with symptomatic ...
BMY's Camzyos shows strong late-stage results in adolescent heart disease, boosting hopes for expanded use as cardiovascular ...
What is Hypertrophic Cardiomyopathy (HCM)? Hypertrophic cardiomyopathy (HCM) is a condition that affects the muscle layer of the heart in patients without any underlying heart problems or systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results